iSWT Community

Cadence

Weekly

Latest

2026-11-01

Based on

12 recent issues

• Covers: East-West biotech deal structures, clinical trial data readouts, regulatory changes, biopharma licensing, and drug development strategies.
• For: Biotech executives, pharmaceutical business development professionals, and cross-border healthcare investors.
• Best for: Biopharma professionals evaluating cross-border asset licensing, regulatory policies, and clinical pipelines.
• Skip if: General consumers or healthcare workers seeking clinical patient care guides.

Start with

• Gilead’s $1.3 Billion Ticket to Join the Oral IL-23 “Biologics In A Pill” Race; U.S. Treasury Proposes to Restrict Investment to China Biotech: Explains biopharma M&A dynamics and proposed US Treasury investment restrictions on Chinese biotech.
• China’s Biotech Export Control Spares Assets Licensing; The Two Cities of mRNA Cancer Vaccines: Analyzes how draft export control rules affect cross-border biotech asset licensing and NewCo formations.
• A 5-Day 12.5-Billion East-West Deal Bonanza; China’s Three 5-Year Plans for Biopharma Industry: Reviews multi-billion dollar cross-border biopharma licensing deals and China's national biopharma strategy.

Sponsors seen

• Lantern SummitPartner

  iSWT Community proudly works with Lantern Summit to offer a few complimentary tickets to our paid subscribers.

  A 5-Day 12.5-Billion East-West Deal Bonanza; China’s Three 5-Year Plans for Biopharma Industry · 2026-10-04

Visit

Summarised by AI from 12 recent issues. Audience size is not included. Prices are not included. Report a mistake.